Microbiome Therapeutics: Global Markets

ReportLinker
·5 min read
ReportLinker
ReportLinker

Report Scope:. BCC Research’s new report, Microbiome Therapeutics: Global Markets, provides a comprehensive analysis of the microbiome therapeutics market in global context, including market forecasts and sales through 2027.

New York, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Microbiome Therapeutics: Global Markets" - https://www.reportlinker.com/p05976892/?utm_source=GNW
The report analyzes the market by segmenting it into the various types of microbiome therapeutics, based on the strategies used for treatment: additive (fecal matter transplants or FMTs, live biotherapeutic products or LBPs), modulatory (postbiotics, prebiotics) and subtractive microbiome therapeutics (phages and antimicrobials).

This study surveys the microbiome therapeutics market by application or disease segment: infectious diseases, metabolic diseases, cancer, gut-brain axis, and others.The market is assessed in the following geographic regions: North America, Europe, and emerging markets.

Emerging markets include countries like India, China, Korea, Taiwan, Africa, Australia, New Zealand, Canada, and Latin America.

The report features leading clinical trials indicating the status and phase of development. New developments and patents are boosting growth of this market in the global context.

The new BCC report provides comprehensive profiles of market players in the industry.The industry structure chapter focuses on the changing market trends, market players and leading pipeline candidates.

This chapter covers influential mergers and acquisitions and other collaborations or partnerships that happened during the evaluation period of this report.

Strengths, weaknesses, threats, and opportunities that are expected to play a role in the microbiome therapeutics market are evaluated in detail.

The markets for prebiotics and probiotics labeled as nutritional or dietary supplements are excluded from this report. Prebiotics and probiotics are included when used in the context of microbiome therapy.

Report Includes:
- 32 data tables and 44 additional tables
- An up-to-date overview and analysis of the global and regional markets for microbiome therapeutics
- Analyses of the global market trends, with historic market revenue (sales data) for 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2027
- Discussion of the industry growth driving factors and major technology challenges and issues affecting the market for microbiome therapeutics as a basis for projecting demand over the next few years (2022-2027)
- Estimation of the actual market size and revenue forecast for global microbiome therapeutics market in USD million terms, and corresponding market share analysis by technology type, application, and region
- Highlights of this innovation driven market covering current trends in genome sequencing industry, disease areas of application, clinical trials and their stages, and recent breakthrough innovations etc.
- Assessment of the recent industry structure for microbiome therapeutics, ongoing research (R&D) activities, analysis of competitive environment, and the COVID-19 impact on the marketplace
- Review of the patents and patent applications on microbiome therapeutics, and related scientific publications during the analysis period
- Competitive landscape of this market featuring leading biopharmaceutical companies, their product portfolios, financial updates, and market share analysis based on recent segmental revenues
- Profile description of the major market participants, including Assembly Biosciences, Finch Therapeutics, Second Genome, Evelo Biosciences, Ysopia Bioscience and Evelo Biosciences

Summary:
The microbiome has become a buzz word and attracted millions of dollars in federal grants, awards and funding from venture capitalists. Technological advancements in next-generation sequencing and data analytics clubbed with modern approaches of systems biology and genetic engineering have greatly expanded the knowledge of commensal microbial populations and interactions with human hosts.

The Human Microbiome Project (HMP), MetaHIT and other independent efforts fueling the exploration of microbiome and its association with human health have led to a research explosion in this area in the last decade. Myriad studies abound showing how the microbiome mediate many physiological processes (metabolism, nutrition, immunity, etc.). Many clinical studies show alterations in microbial populations or microbial dysbiosis can lead to disease. Restoration of the microbiome addresses many unmet medical needs. Diseases that still do not have definitive cures or with available treatments that are either not satisfactory or are cost-prohibitive, are actively targeted by microbiome therapeutics.

There are many active players in the field of microbiome therapeutics, ranging from discovery and clinical-stage to late-stage companies that are exploiting different approaches to modulate the microbiome.Fecal microbial transplants (FMTs) have been in practice for some time and the use of live biotherapeutic products (LBPs) in the form of single strains or microbial consortia is a popular strategy with targeted mechanisms and controlled production processes.

The development of small molecule drugs (postbiotics) and the use of phages are being actively explored.

Currently, no microbiome therapeutic is approved in the U.S. or in any other market. There are some candidates in Phase 3 trials (Seres Therapeutics SER109 and Rebiotix’s RBX2660) that are being evaluated for the treatment of recurrent Clostridium difficile infection. Despite an expansive patent portfolio and a large number of clinical trials in the field of microbiome therapeutics, the market is facing some challenges. The absence of any regulatory framework brings uncertainty for many developers in this novel market. The complexity of the human microbiome and variations among different individuals add to difficulties in the design of clinical trials. Additional hurdles are expected during scaling.

For the microbiome therapeutics market to grow, a strong collaborative effort is needed from all stakeholders, including the regulatory agencies. Statistically-relevant results and proof-of-concept studies driven by technological advancements in biomarkers, functional assays and computational biology are required that will eventually pave the way for product approvals.
Read the full report: https://www.reportlinker.com/p05976892/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Latest Stories

  • EMERGING MARKETS-Latam FX extends gains to eighth day, Brazil real lags ahead of fiscal framework

    * Mexico's Banorte to add 800 jobs to tap into nearshoring * Chile's peso briefly hits 5-week highs * Brazilian real inches up ahead of fiscal framework * Peru prosecutors probe president, ex-president for alleged money laundering * Latam FX up 0.6%, EM currencies slip 0.1% (Updates prices, details; adds comment) By Shreyashi Sanyal and Bansari Mayur Kamdar March 29 (Reuters) - Latin American currencies outperformed emerging market peers on Wednesday, while the Brazilian real made small advances as President Luiz Inacio Lula da Silva was set to finalize the proposal for a new fiscal framework later in the day. The MSCI's index for Latin American currencies added 0.6%, extending its rally for eighth straight session.

  • Mel King, who helped ease Boston's racial strife, dies at 94

    Longtime Boston civil rights activist Mel King, whose 1983 campaign for mayor helped the city begin to repair some of the racial divisions sparked during the school busing crisis, has died. King served in the state Legislature for nearly a decade before becoming the first Black man to reach a Boston general mayoral contest, facing off against a fellow state representative, Ray Flynn. Flynn, who represented the predominantly white, Irish neighborhood of South Boston, was an opponent of busing.

  • TCU Insider: Newcomers continue to impress in spring practice

    TCU’s new influx of talent is turning heads midway through spring practice

  • Former Starbucks CEO testifies during Senate hearing on treatment of employees unionizing

    Former Starbucks CEO Howard Schultz said in a Senate hearing Wednesday the coffee company did not break the law.

  • UPDATE 1-U.S. retail sales to grow at slower pace in 2023 - NRF

    Retail sales in the United States are expected to grow at a slower pace this year, the National Retail Federation (NRF) said on Wednesday, as fears of a recession and tremors in the banking industry cast a shadow over a recovery in consumer spending. The trade body said it expects retail sales to rise between 4% and 6% to up to $5.23 trillion, in comparison to 7% growth in 2022 to $4.9 trillion. Last year, the retail industry took a beating due to stubbornly high inflation and dwindling discretionary budgets at American households that left companies ranging from Walmart Inc to Macy's Inc with excess inventories.

  • Ex-Tesla worker suing for race bias takes stand in damages trial

    A Black former elevator operator at Tesla Inc's flagship California assembly plant began testifying on Wednesday in a trial over how much the electric vehicle maker must pay for subjecting him to severe racial harassment by coworkers. The plaintiff, Owen Diaz, is expected to testify for roughly four hours about the psychological toll exacted on him by a torrent of racial slurs, threats and other incidents during the nine months in 2015 that he worked at the automaker's factory in Fremont, California. Diaz's testimony will likely stretch into Thursday.

  • Number of homeless families in Tarrant County increase 27% as rents, evictions rise

    “We really don’t have any shelter beds available.”

  • New boba tea restaurant opens in Folsom. Owners plan to expand in the Sacramento region

    The ingredients are locally sourced, the fruits are fresh and the milk is organic, according to the owner.

  • UPDATE 1-White House to China: Don't use Taiwan visit as 'pretext'

    The White House urged China on Wednesday not to use a "normal" stopover in the United States by Taiwan's president as a pretext to increase aggressive activity against Taiwan. John Kirby, the White House national security spokesperson, told reporters that Taiwan President Tsai Ing-wen's arrival soon in the United States is the latest in a series of routine transits. "The Peoples Republic of China should not use this transit as a pretext to step up any activity around the Taiwan strait," he said.

  • Hurry! Amazon Warehouse's secret deals — from Apple to PlayStation — are about to sell out

    Some products are open-box, some are pre-owned and all are guaranteed.

  • Head teacher 'headed straight for shooter' during Nashville school massacre

    The head teacher gunned down at a Christian primary school in Nashville headed "straight for the shooter" to protect her pupils, it emerged, as vigils were held across the city.

  • Is LeBron James coming to Mavs? The Ringer’s Bill Simmons believes so

    Simmons thinks Draymond and Lebron are destined for the Lone Star State

  • Police standoff with armed woman continues on busy Virginia road over 24 hours after it started

    According to the Fairfax County Police Department, the standoff with the woman began about 11 a.m. Tuesday and continued on Wednesday.

  • Anthony Joshua: I am focused on fighting Tyson Fury – but will retire if I lose to Jermaine Franklin

    Anthony Joshua, the former world heavyweight champion, has warned he will retire if he loses to Jermaine Franklin at the O2 Arena on Saturday but insisted he was concentrating on victory and a possible crack at arch rival Tyson Fury this summer.

  • Cleo Parker Robinson Honored

    Cleo Parker Robinson received the National Medal of the Arts at The White House.

  • Murdaugh judge Newman not surprised by jury's quick verdict

    The judge who presided over Alex Murdaugh's murder trial in South Carolina told his law school he wasn't surprised the jury came back with a guilty verdict in three hours. Judge Clifton Newman returned to Cleveland State University where he earned his law degree in 1976 to discuss his career and the topic on everyone's minds — the six-week trial that ended in Murdaugh's murder convictions for killing his wife and son and life sentence.

  • Lamborghini's plug-in hybrid supercar runs for a cool six miles in electric-only mode

    Lamborghini just announced the 2024 Revuelto, a plug-in hybrid supercar that gets just six miles of all-electric usage per charge but features a charging mechanism within the combustion engine. Beyond the battery, the engine specs are outstanding and the form factor is aerospace-inspired, with sculpted surfaces and hexagonal exhausts.

  • TVLine Items: Awkwafina Is Nora Return Date, Ninja Warrior Renewed and More

    No, Comedy Central hasn’t forgotten about Awkwafina Is Nora From Queens. The comedy series will return for Season 3 on Wednesday, April 26 at 10:30/9:30c, a full 18 months after the Season 2 finale, which aired in October 2021. The premiere date announcement was reported by our sister site Variety, which also unveiled a new […]

  • How to Xeriscape Your Garden

    Take watering off of your to-do list with smarter landscaping.

  • Here's Why Stratasys Stock Traded Higher Today

    Shares of 3D-printer company Stratasys (NASDAQ: SSYS) traded higher on Wednesday after the company received a new buyout offer from Nano Dimension (NASDAQ: NNDM). For its part, Nano Dimension stock was flat. Nano Dimension is offering to buy Stratasys for $19.55 per share, representing a 38% premium to where the stock traded before the market opened this morning.